SCHEMBL7115204

SCHEMBL7115204

CN(C)c1cc(N(NC(=O)CC(=O)c2cccc(-c3cccnc3)c2)C(=O)OC(C)(C)C)ccc1C(F)(F)F

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMO O15229 1/20 0.36
ABL1 P00519 1/20 0.35
BCR P11274 1/20 0.35
HDAC1 Q13547 1/20 0.35
SCN5A Q14524 5/20 0.35
SCN9A Q15858 5/20 0.35
CFTR P13569 1/20 0.35
CSF1R P07333 2/20 0.34
KIT P10721 2/20 0.34
EGFR P00533 1/20 0.34
CYP1A2 P05177 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
HTR2B P41595 1/20 0.33
TSPO P30536 1/20 0.33
GPR119 Q8TDV5 1/20 0.33
PLOD2 O00469 1/20 0.33
PLOD3 O60568 1/20 0.33
PLOD1 Q02809 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7112784 0.86 SCN5A (0.35) KMOSCN5ASCN9ACFTRCSF1R
SCHEMBL7114425 0.84 PLOD2 (0.42) SCN5ASCN9ACSF1RKITCYP1A2
SCHEMBL7151045 0.83 CNR1 (0.41) KMOABL1BCRHDAC1EGFR
SCHEMBL7113378 0.82 ABL1 (0.38) ABL1BCRSCN5ASCN9ACSF1R
SCHEMBL7117074 0.81 ABL1 (0.39) ABL1BCRSCN5ASCN9A
SCHEMBL5566520 0.81 RXRA (0.32)
SCHEMBL7109630 0.80 CSF1R (0.38) SCN5ASCN9ACSF1RKIT
SCHEMBL5557828 0.79 SCN5A (0.41) KMOSCN5ASCN9ACFTRCSF1R
SCHEMBL7113350 0.79 RXRA (0.40) KIT
SCHEMBL7047983 0.77 AAK1 (0.33) KMOABL1BCRHDAC1SCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1474416-A1 DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2004-11-10 EP disclosed
WO-2003066623-A1 DIHYDROBENZODIAZEPIN-2-ONE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2003-08-14 WO disclosed